



Australian Government

Department of Health, Disability and Ageing Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 330206 Ultra Muscleze P5P

ARTG entry for	Medicine Listed
Sponsor	FIT-BioCeuticals Pty Ltd
Postal Address	Blackmores Limited, PO Box 1725, Warriewood, NSW, 2102 Australia
ARTG Start Date	20/02/2020
Product Category	Medicine
Status	Active
Approval Area	Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Ultra Muscleze P5P

Product Type	Single Medicine Product	Effective Date	3/09/2025
---------------------	-------------------------	-----------------------	-----------

Permitted Indications

Maintain/support energy production
Maintain/support physical endurance/capacity/stamina when dietary intake is inadequate in athletes
Relieve weariness/tiredness/fatigue/feeling of weakness
Maintain/support bone health
Maintain/support cardiovascular system health
Maintain/support healthy cardiovascular system function
Decrease/reduce/relieve muscle cramps when dietary intake is inadequate
Helps decrease/reduce/relieve mild muscle spasms/twitches when dietary intake is inadequate
Maintain/support healthy muscle contraction function
Maintain/support muscle function
Maintain/support healthy neuromuscular system/function
Maintain/support muscle relaxation
Aid/assist/helps protein synthesis in the body
Support healthy stress response in the body
Maintain/support nerve conduction
Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system function
Decrease/reduce feelings of aggression/irritability associated with premenstrual tension
Decrease/reduce mood changes/mood swings associated with premenstrual tension
Decrease/reduce/relieve breast pain/tenderness associated with premenstrual tension
Decrease/reduce/relieve symptoms of premenstrual tension
Decrease/reduce/relieve morning sickness

Indication Requirements

If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Product presentation must not imply or refer to chronic fatigue syndrome.



Australian Government

Department of Health, Disability and Ageing Therapeutic Goods Administration

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of the table in Part 2 of Schedule 1 to this instrument are also used.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible.
[Contains vitamin B6].

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

magnesium glycinate	477 mg
Equivalent: magnesium	67.2 mg
magnesium oxide	137 mg
Equivalent: magnesium	82.8 mg
pyridoxal 5-phosphate monohydrate	53.7 mg
Equivalent: pyridoxine	34.23 mg

Other Ingredients (Excipients)

Carnauba Wax

chlorophyllin-copper complex

citric acid

colloidal anhydrous silica

croscarmellose sodium

crospovidone

hypromellose

macrogol 3350

magnesium stearate

maltodextrin

microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary